Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Zhejiang Medicine In-Licenses Novel Antibiotic from TaiGen

publication date: Jun 25, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Zhejiang Medicine Company has in-licensed China rights to manufacture and commercialize a broad-spectrum antibiotic from TaiGen Biotechnology of Taiwan. ZMC will pay $8 million upfront for the license. Nemonoxacin is a novel non-fluorinated quinolone antibiotic, currently completing a Phase III clinical trial for community acquired pneumonia in China and Taiwan. TaiGen expects to file for SFDA approval of the antibiotic in early 2013. More details....

Stock Symbol: (SHA: 600216)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
Hope to see you there!
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors